Search clinical trials for: Ligelizumab

Total 31 results

Novartis Pharmaceuticals

No longer available

Global Managed Access Program Cohort for Ligelizumab in CSU

Chronic Spontaneous Urticaria
Novartis Pharmaceuticals

Completed

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

Chronic Spontaneous Urticaria

United States, Spain, Germany, Taiwan, Japan, Australia, Russian Federation, Greece, Canada, United Kingdom
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

Allergy, Peanut

United States, Germany, Japan, Australia, France, Spain, Denmark, Canada, Italy, Netherlands
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

Chronic Spontaneous Urticaria

United States, Spain, Belgium, Croatia, Germany, Hungary, India, Malaysia, Russian Federation, Taiwan, Turkey, Netherlands, Italy, Australia, Israel, Korea, Republic of, Lebanon, Greece, Singapore, Slovakia, Thailand, Austria, Bulgaria and more
Novartis Pharmaceuticals

Completed

Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria

Taiwan, Turkey, Belgium, Spain, Germany, India, Argentina, Canada, Russian Federation, Hungary
Novartis Pharmaceuticals

Completed

A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines

Chronic Spontaneous Urticaria

Japan
Novartis Pharmaceuticals

Terminated

Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria (MASTER)

Chronic Spontaneous Urticaria | Cold Urticaria | Cholinergic Urticaria

Germany
Novartis Pharmaceuticals

Recruiting

Long-term Extension Study of Ligelizumab in Food Allergy

Food Allergy

United States, Spain, France, Germany, Italy, Netherlands, Canada, Japan, Australia
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines (PEARL-PROVOKE)

Chronic Inducible Urticaria

Taiwan, Turkey, United States, Australia, Hungary, Spain, Greece, Russian Federation, Slovakia
Second Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer

Non-small Cell Lung Cancer
Zhejiang Cancer Hospital

Recruiting

Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Locally Advanced Gastric Cancer

China
Zhongshan People's Hospital, Guangdong, China

Recruiting

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Novartis Pharmaceuticals

Completed

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

Chronic Spontaneous Urticaria

United States, Poland, Spain, Belgium, Germany, Russian Federation, Taiwan, Netherlands, Italy, Australia, France, Israel, Lebanon, Slovakia, India, Japan, Estonia, Philippines, Mexico, Argentina, United Kingdom, Vietnam, Brazil, Romania and more
Eye & ENT Hospital of Fudan University

Not yet recruiting

Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Tianjin Medical University Cancer Institute and...

Recruiting

Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations

Colon Cancer | Immunotherapy | MSI-H | Adjuvant Therapy

China
Novartis Pharmaceuticals

Completed

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Chronic Spontaneous Urticaria

United States, Croatia, Hungary, India, Malaysia, Spain, Germany, Austria, Czechia, Denmark, France, Korea, Republic of, Greece, Singapore, Thailand, Bulgaria, Argentina, Turkey, Guatemala, Brazil, Russian Federation, Peru, Canada, Sw... and more
Yixing People's Hospital

Recruiting

Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery

Gastric Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status

Colorectal Cancer | Liver Metastases

China
Gang Wu

Not yet recruiting

Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC

Carcinoma, Non-Small Cell Lung
First Affiliated Hospital of Zhejiang University
BeiGene (Beijing) Co., Ltd

Recruiting

TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC

BCLC Stage C Hepatocellular Carcinoma

China
Fudan University

Not yet recruiting

Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma

PFS
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC

Stomach Cancer

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC (ETNT)

Esophageal Squamous Cell Carcinoma

China
Dong Jie

Terminated

Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients

Restless Legs Syndrome

China
Huihua Xiong

Recruiting

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study (UTILIZABLE)

TNBC - Triple-Negative Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC (HNC-SYSU-001)

Head and Neck Squamous Cell Carcinoma | Oral Cancer

China
Chen Xiaoping

Not yet recruiting

Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.

HCC
Fudan University

Recruiting

Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy (Castle06(BC))

Metastatic Breast Cancer in the Liver

China
Ruijin Hospital

Recruiting

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Advanced Non-squamous Non-small Cell Lung Cancer

China
Affiliated Cancer Hospital & Institute of Guangzhou...

Not yet recruiting

Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

Non Small Cell Lung Cancer | Endostatin

China

Search clinical trials for: Ligelizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations